PAPAVERINE

Possibly Marketed Outside US

First approved in 1995

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H21NO4
Molecular Weight	339.385
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1

InChI

InChIKey=XQYZDYMELSJDRZ-UHFFFAOYSA-N

InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3

HIDE SMILES / InChI

Description
Sources: https://www.drugs.com/cdi/papaverine.html | https://www.ncbi.nlm.nih.gov/pubmed/16780899 | https://www.ncbi.nlm.nih.gov/pubmed/16159054 | https://media.fepblue.org/-/media/pdfs/medical%20policies/10-15-14/pharma/5_06_19_papaverine_powder.pdf

An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. Papaverine is a vasodilating agent. Papaverine is used for the treating certain conditions that are accompanied by smooth muscle spasms (eg, blood vessel, urinary, gallbladder, or intestinal spasm). Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries. Papaverine is a potent, specific inhibitor of PDE10A. Papaverine for treatment of erectile dysfunction (ED) is excluded from coverage.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Phosphodiesterase 10A 13 Target ID: CHEMBL4409 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16780899 \| https://www.ncbi.nlm.nih.gov/pubmed/20447563 \| https://www.ncbi.nlm.nih.gov/pubmed/21705115	Inhibitor 8504	36.0 nM [IC50]
Human immunodeficiency virus 8 Target ID: CHEMBL613758 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2713167 \| https://www.ncbi.nlm.nih.gov/pubmed/7506701	Inhibitor 8504
Telomerase reverse transcriptase 10 Target ID: CHEMBL2916 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25111025	Inhibitor 8504	60.0 µM [IC50]
HERG 99 Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19034039	Inhibitor 8504	0.58 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Spasm of smooth muscle 5 Sources: https://www.drugs.com/cdi/papaverine.html	Primary		Approved 8583	Papaverine Approved Use Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic.

C_max

Value	Dose	Analyte	Population
54.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24217241/	3 mg single, intravascular dose: 3 mg route of administration: Intravascular experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
583 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
117 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
536 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
218 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
1760 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3413033/	80 mg single, intravenous dose: 80 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
375 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3413033/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1965 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3413033/	80 mg single, intravenous dose: 80 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
855 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3413033/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1308 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
409 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1247 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
800 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/489763/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3413033/	80 mg single, intravenous dose: 80 mg route of administration: Intravenous experiment type: SINGLE co-administered:		PAPAVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3413033/	80 mg single, intravenous dose: 80 mg route of administration: Intravenous experiment type: SINGLE co-administered:		PAPAVERINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
500 mg 3 times / day multiple, oral Higher than recommended Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6340562/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6340562/	Disc. AE: Alkaline phosphatase increased, SGOT increased... AEs leading to discontinuation/dose reduction: Alkaline phosphatase increased (4%) SGOT increased (4%) Eosinophilia (4%) Sources: https://pubmed.ncbi.nlm.nih.gov/6340562/
15 g single, oral Overdose Dose: 15 g Route: oral Route: single Dose: 15 g Sources: https://pubmed.ncbi.nlm.nih.gov/7248034/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7248034/	Disc. AE: Consciousness decreased, Respiration abnormal... AEs leading to discontinuation/dose reduction: Consciousness decreased Respiration abnormal Metabolic acidosis Respiratory alkalosis Sinus tachycardia Hypokalemia (grade 2) Hyperglycemia (grade 1) Pyruvate increased Sources: https://pubmed.ncbi.nlm.nih.gov/7248034/
8 g single, oral Overdose Dose: 8 g Route: oral Route: single Dose: 8 g Sources: https://pubmed.ncbi.nlm.nih.gov/12811723/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/12811723/	Disc. AE: Lactic acidosis, Hypokalemia... AEs leading to discontinuation/dose reduction: Lactic acidosis (grade 3) Hypokalemia Coma (grade 5) Convulsions (grade 3) Vomiting (grade 3) Respiratory alkalosis (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/12811723/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2A6 879 CYP1A2 2153 CYP2E1 1060 CYP2C19 2057 MRP4 290 OATP1B1 1079 MRP3 246 BSEP 550 OATP1B3 961 OCT1 620 MRP2 499	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	inconclusive [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTkyMjQifX0=	inconclusive [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	no [IC50 >10 uM]
MRP2 625	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1NzQ4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	no [IC50 >133 uM]
MRP3 326	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1OTE4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	no [IC50 >133 uM]
OCT1 656	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1Njg1IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	weak [Inhibition 100 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	yes [IC50 0.762 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTkyMjQifX0=	yes [IC50 1.9953 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	yes [IC50 12.5893 uM]
MRP4 345	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	yes [IC50 23.13 uM]
BSEP 554	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MDIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MjI0In19	yes [IC50 <10 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk4MTIzIn19	yes [Inhibition 10 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk4MTIzIn19	yes [Inhibition 10 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/4680#section=BioAssay-Results Page: 575 \| 580	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTkyMjQifX0=

PubMed

Title	Date	PubMed
Papaverine-induced chronic liver disease.	1986 Apr	3949106
Maintenance treatment of erectile impotence by cavernosal unstriated muscle relaxant injection.	1986 Aug	3640652
Incompatibility of Hexabrix and papaverine in peripheral arteriography.	1987 Mar	3809473
Pressor inhibition of angiotensin-induced ACTH secretion.	1987 Nov	2835134
Diagnosis of male impotence after intracavernous papaverine test.	1988	3215253
[Efficacy of vascular therapy in complex of treatment of purulent necrotic foot ulcers in patients with diabetes mellitus].	2001 Feb	11482020
Papaverine blocks hKv1.5 channel current and human atrial ultrarapid delayed rectifier K+ currents.	2003 Feb	12538825
Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells.	2003 Sep	12714375
[X-ray densitometric measurement of myocardial perfusion reserve in symptomatic patients without angiographically detectable coronary stenoses].	2008 Apr	18568317
Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition.	2008 Dec	18493746
Insulin resistance functionally limits endothelium-dependent coronary vasodilation in nondiabetic patients.	2008 Jan	18273540
Adverse effects of topical papaverine on auditory nerve function.	2008 Sep	18726058
Abnormal responses of the human cerebral microcirculation to papaverin during aneurysm surgery.	2009 Jan	18845800

Patents

Sample Use Guides

In Vivo Use Guide

Papaverine Hydrochloride may be administered intravenously or intramuscularly. The intravenous route is recommended when an immediate effect is desired, but the drug must be injected slowly over the course of 1 or 2 minutes to avoid uncomfortable or alarming side effects. Parenteral administration of papaverine hydrochloride in doses of 1 to 4 mL is repeated every 3 hours as indicated. In the treatment of cardiac extrasystoles, 2 doses may be given 10 minutes apart.

Route of Administration: Parenteral

In Vitro Use Guide

In bovine cauda epididymal and ejaculated spermatozoa, the major cAMP-PDE activity was papaverine-sensitive (44.5% and 57.5%, respectively, at 400 nm of papaverine).

Name

Type

Language

PAPAVERINUM

Preferred Name

English

PAPAVERINE

Common Name

English

PAPAVERINE [MART.]

Common Name

English

PAPAVERINUM [HPUS]

Common Name

English

NSC-136630

Code

English

6,7-DIMETHOXY-1-VERATRYLISOQUINOLINE

Systematic Name

English

ISOQUINOLINE, 1-((3,4-DIMETHOXYPHENYL)METHYL)-6,7-DIMETHOXY-

Systematic Name

English

NOSCAPINE IMPURITY A [EP IMPURITY]

Common Name

English

PAPAVERINE [MI]

Common Name

English

Papaverine [WHO-DD]

Common Name

English

PAPAVERINE [VANDF]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QG04BE02